Nintedanib is used for the treatment of progressive fibrosing interstitial lung disease (PF-ILD) with a broad range of underlying diagnoses and variation in disease severity at the point of initiation. Real-world data suggest an acceptable tolerability profile of nintedanib in PF-ILD.
Access the article | Submit your manuscript to ERJ Open Research
Friday, 2 February 2024
ERJ Open Research: pick of the week
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment